{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:44:42Z","timestamp":1776743082073,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2025.10.018","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:14:52Z","timestamp":1762215292000},"page":"e460-e469.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic Hematopoietic Stem Cell Transplantation Abrogates the Poor Prognosis of High-Risk Cytogenetics in Adult Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6824-8320","authenticated-orcid":false,"given":"Lin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Maleki Goli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parnia","family":"Ghanad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingqian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5603-4160","authenticated-orcid":false,"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2025.10.018_bib0001","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1468-0734.2002.00069.x","article-title":"Cytogenetics and molecular genetics of acute lymphoblastic leukemia","volume":"6","author":"Harrison","year":"2002","journal-title":"Rev Clin Exp Hematol"},{"issue":"12","key":"10.1016\/j.clml.2025.10.018_bib0002","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/leu.2014.142","article-title":"A revised definition for cure of childhood acute lymphoblastic leukemia","volume":"28","author":"Pui","year":"2014","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.clml.2025.10.018_bib0003","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1002\/cncr.29573","article-title":"Childhood acute lymphoblastic leukemia: integrating genomics into therapy","volume":"121","author":"Tasian","year":"2015","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2025.10.018_bib0004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","article-title":"Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97\/99 randomised trial","volume":"11","author":"Moorman","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.10.018_bib0005","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","article-title":"A population-based cytogenetic study of adults with acute lymphoblastic leukemia","volume":"115","author":"Moorman","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.10.018_bib0006","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cncr.30376","article-title":"Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease","volume":"123","author":"Issa","year":"2017","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2025.10.018_bib0007","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.10.018_bib0008","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood-2017-05-783852","article-title":"Impact of cytogenetic abnormalities in adults with ph-negative B-cell precursor acute lymphoblastic leukemia","volume":"130","author":"Lafage-Pochitaloff","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.10.018_bib0009","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3324\/haematol.2019.220756","volume":"105","author":"Lazaryan","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2025.10.018_bib0010","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1038\/s41375-021-01135-2","volume":"35","author":"Esteve","year":"2021","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.clml.2025.10.018_bib0011","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.10.018_bib0012","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/cncr.35232","article-title":"Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: a multicenter retrospective study","volume":"130","author":"Guan","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2025.10.018_bib0013","article-title":"ISCN 2020. An International System for Human Cytogenomic Nomenclature (2020)","volume":"47","author":"Moore","year":"2021","journal-title":"J Assoc Genet Technol"},{"issue":"9","key":"10.1016\/j.clml.2025.10.018_bib0014","first-page":"705","article-title":"Chinese guidelines for diagnosis and treatment of adult acute lymphoblastic leukemia (2021)","volume":"42","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"10","key":"10.1016\/j.clml.2025.10.018_bib0015","first-page":"837","article-title":"Chinese guidelines for diagnosis and treatment of acute lymphoblastic leukemia(2016)","volume":"37","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"17","key":"10.1016\/j.clml.2025.10.018_bib0016","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","article-title":"T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT","volume":"124","author":"Luo","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2025.10.018_bib0017","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1182\/bloodadvances.2021004580","article-title":"Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience","volume":"5","author":"Richard-Carpentier","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2025.10.018_bib0018","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/s41375-019-0394-z","article-title":"The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells","volume":"33","author":"Zhang","year":"2019","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.clml.2025.10.018_bib0019","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood.2023021501","article-title":"Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study","volume":"142","author":"Kim","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.10.018_bib0020","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.22.01297","article-title":"Outcomes of childhood noninfant acute lymphoblastic leukemia with 11q23\/KMT2A rearrangements in a modern therapy era: a retrospective international study","volume":"41","author":"Attarbaschi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.10.018_bib0021","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2004-07-2922","article-title":"A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol","volume":"105","author":"Mancini","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.10.018_bib0022","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.10.018_bib0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.2023023153","article-title":"How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults","volume":"145","author":"Tran","year":"2025","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2025.10.018_bib0024","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2025.10.018_bib0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.semdp.2023.04.003","article-title":"Emerging molecular subtypes and therapies in acute lymphoblastic leukemia","volume":"40","author":"Davis","year":"2023","journal-title":"Semin Diagn Pathol"},{"issue":"4","key":"10.1016\/j.clml.2025.10.018_bib0026","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2141.2005.05497.x","article-title":"Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group study","volume":"129","author":"Harrison","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.10.018_bib0027","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/sj.leu.2404372","article-title":"Identification of cryptic aberrations and characterization of translocation breakpoints using array CGH in high hyperdiploid childhood acute lymphoblastic leukemia","volume":"20","author":"Paulsson","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.10.018_bib0028","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/2643-3230.BCD-21-0163","article-title":"ZNF384 Fusion oncoproteins drive lineage aberrancy in acute leukemia","volume":"3","author":"Dickerson","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"10.1016\/j.clml.2025.10.018_bib0029","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3324\/haematol.2013.094284","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the E","volume":"99","author":"Lussana","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.10.018_bib0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40164-015-0015-0","article-title":"Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning","volume":"4","author":"Imamura","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.10.018_bib0031","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","article-title":"The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission","volume":"116","author":"Marks","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.10.018_bib0032","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bmt.2013.68","article-title":"Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)","volume":"48","author":"Tanaka","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2025.10.018_bib0033","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41409-024-02282-7","article-title":"Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)","volume":"59","author":"Niederwieser","year":"2024","journal-title":"Bone Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:17:23Z","timestamp":1776741443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265025042600"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Hematopoietic Stem Cell Transplantation Abrogates the Poor Prognosis of High-Risk Cytogenetics in Adult Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}